Oncology providers familiar with the American Society of Clinical Oncology’s (ASCO) guideline on older adults with cancer are two to four times more likely to conduct a geriatric assessment on patients with cancer over the age of 65, according to the first international ASCO survey aimed at determining if and how often cancer providers are using geriatric assessments when treating older adults. This is a noteworthy finding, according to ASCO, because nearly 70% of patients with cancer in the United States are 65 years of age or older, and globally, the number of new cancer cases per year among older adults will exceed 13 million by 2030.
Statement by ASCO President Howard A. "Skip" Burris III, MD, FACP, FASCO, applauding the Surgeon General for releasing its first report on smoking cessation in 30 years.
The American Society of Clinical Oncology (ASCO) today published standards on the safe handling of hazardous drugs in the Journal of Clinical Oncology. ASCO’s standards largely endorse best practices issued by other stakeholder groups for safely handling hazardous drugs but offer alternatives in several key areas where more research is needed to identify evidence-based safety measures.
ARLINGTON, Va., ALEXANDRIA, Va., CHICAGO, October 11, 2018 — Three prominent medical societies today issued a new clinical guideline for physicians treating men with early-stage prostate cancer using external beam radiation therapy (EBRT). Adoption of the guideline could make treatment shorter and more convenient for many patients with prostate cancer, the most common malignancy among American men.
Alexandria, Va. - Use of tests that assess genomic variants in circulating tumor DNA (ctDNA) is on the rise. A new joint review from the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) provides an assessment of evidence on ctDNA tests in oncology. It also lays out a framework for future research and clinical practice guidelines to help better inform clinical practice.
ALEXANDRIA, VA, FORT WASHINGTON, PA. – Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body’s immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into lasting remission.
ALEXANDRIA, Va. - Effective clinician communication is a core element of all patient-centered oncology care. The complexities of cancer, and its ever-present association with mortality, require specialized communication skills.
ALEXANDRIA, Va. - An update of the American Society of Clinical Oncology (ASCO) clinical practice guideline clarifies the role of immunotherapy in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). The update also provides new recommendations on the use of targeted therapies for patients with changes in tumor EGFR, ALK, and ROS1 genes.
ALEXANDRIA, Va. - An update of the American Society of Clinical Oncology (ASCO) clinical practice guideline covers new medicines for nausea and vomiting related to cancer treatment. The update, issued today, provides new evidence-based information on the appropriate use of olanzapine, NK1 receptor antagonists and dexamethasone.
ALEXANDRIA, Va. - New recommendations on the use of the MammaPrint genomic test issued today will help guide decisions on adjuvant systemic therapy for women with early breast cancer. The recommendations update the American Society of Clinical Oncology (ASCO) 2016 clinical practice guideline on the use of biomarkers in these patients.
NORTHFIELD, Ill. and ALEXANDRIA, Va. – Draft recommendations as part of a focused update to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer are now open for public comment through June 12, 2017.
ALEXANDRIA, Va. —The American Society of Clinical Oncology (ASCO) today issued a provisional clinical opinion (PCO) on the use of second-line hormonal therapy for men with castration-resistant prostate cancer (CRPC) who have not yet received chemotherapy.
ALEXANDRIA, Va., Toronto, Canada - The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer. The update provides evidence-based recommendations for different patient risk groups, and specifies the most effective forms of brachytherapy.
ALEXANDRIA, Va. - The American Society of Clinical Oncology (ASCO) today issued a clinical practice guideline on human papillomavirus (HPV) vaccination for the prevention of cervical cancer. This is the first guideline on primary prevention of cervical cancer that is tailored to multiple regions of the world with different levels of socio-economic and structural resource settings, offering evidence-based guidance to health care providers worldwide.
Chicago, Northfield, IL, Bethesda, MD, Alexandria, VA—A new, evidenced-based clinical practice guideline on molecular biomarker testing for patients with colorectal cancer identifies opportunities for improving patient outcomes.